February 7, 2014
The Second Wave Arrives
Two more HCV drugs were newly approved in late 2013: the protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi).
By comparison to the two previously approved HCV protease inhibitors, simeprevir appears to be significantly more friendly toward coadministration with HIV medications (particularly HIV protease inhibitors) and has a high efficacy rate in HCV treatment-naive coinfected patients, even allowing many to dramatically shorten the typical course of HCV therapy. However, the drug must still be coadministered with peginterferon, leaving toxicity as a major issue.
Peginterferon is also part of a sofosbuvir-containing regimen at the moment, but only for genotype 1 patients. For patients with genotype 2 or 3, the drug is dosed alongside only ribavirin, and dramatically lower adverse event rates accompany that indication. Sofosbuvir also appears to have virtually no interactions with HIV antiretrovirals.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|An Airplane, a Missile, and an Unfathomable Moment in the War Against HIV|
|Coverage of AIDS 2014: The 20th International AIDS Conference|
|No Longer Cured: HIV Relapse in "Mississippi Child" Raises New Questions|
|AIDS 2014 to Focus on Scaling Up What Works|
|I'm an HIV Physician. And I'm Starting PrEP. A Blog Entry by Howard Grossman, M.D.|
|Amidst Sadness, AIDS 2014 to Proceed as Global HIV Community Mourns Lost Leaders|